Please cite this article in press Ashish D. Gadge et al., A Detailed Review On Formulation And Characterization Of An Immediate Release Solid Oral Dosage Form Containing An Estrogen Derivative, Indo Am. J. P. Sci, 2025; 12(04).

1. Dutt, K., & Sharma, S. S.S. S.S. IMMEDIATE DRUG RELEASE TABLETS: A REVIEW IMMEDIATE DRUG RELEASE TABLETS: A REVIEW.
2. Pantle, V., Karale, P., Goje, P., & Mahanavar, S. (2016). An overview on emerging trends in immediate release tab]et technologies. Austin Therapeutics, 3(1), 1026.
3. Buwade, P., Jadjya, S., Shukla, T., & Upmaoyu, 0. N. (2015). Advantages of im:mecliate release tablets over the other tablet forms. World Journal of Pharmaceutical Research, 4(11), 757-780.
4. Nyol, Sandeep, and M. M. Gupta. “Immediate drug release dosage form: a review.”
Journal of Drug Delivery and Therapeutics 3.2 (2013).
5. Iqubal, Mohammad Kashif, et al. “Recent advances in direct compression technique for pharmaceutical tablet formulation.” Int J Pharm Res & Devel 6.1 (2014): 49-57.
6. Kleinebudde, P. (2004). Roll compaction/dry granulation: pharmaceutical applications.
European Journal of Pharmaceutics and biopharmaceutics, 58(2), 317- 326.
7. Agrawal, R., & Naveen, Y. (2011). Phannaceutical processing-A review on wet granulation technology. International journal of pharmaceutical frontier research, 1(1), 65-83.
8. Chaudhari, S. P., & Patil, P. S. (2012). Pharmaceutical excipients: a review. Int 1 Adv Pharm Biol Chem, 1(1), 21-34.
9. Kalasz, H., & Antal, I. (2006). Drug excipients. Current medicinal chemistry, 13(21), 2535-2563.
10. Dharani, T., Kumar, P. P., Phanindra, D.S., Nagabhushanam, M. V., Bonthagarala, B., Ramakrishna, G., … & Ch, S. K. (2022). A REVIEW ON ABBREVIATED NEW DRUG APPLICATION (ANDA).
11. Sharmila, S. K., Bonthagarala, B., Nagabhushanam, M. V., Ramakrishna, G., & Sindhu,
S. Y. R. (2021). ABBREVIATED NEW DRUG APPLICATION (ANDA) FILING CHECKLIST.
12. Vishal, P., Rahulgiri, G., Pratik, M., & Kumar, B. J. (2014). A review on drug approval process for US, Europe and India. lnt J Drug Regul Aff, 2, 1-11.
13. Berndt, E. R., Mo1timer, R., Bhattacharjya, A., Parece, A., & Tuttle, E. (2007). Authorized generic drugs, price competition, and consumers’ welfare. Health Affairs, 26(3), 790-799.
14. GORREMUTCHU, S. K., REDDY, D. N., GOPAL, P., & NAGABHUSHANAM, M. LATEST DEVELOPMENTS REQUIRED FOR THE PROCEDURE INVOLVED IN US ANDA FILING.
15. Nagori, B. P., Mathur, V., & Garg, S. (2011). Generic drug approval: a US perspective.
Current medical research and opinion, 27(3), 541-545.
16. Dixit, A., Kumar, N., & Kumar, S. (2018). Use of genetic medicines: Challenges and benefits. Journal of health management, 20(1), 84-90.
17. Sherif, K. (1999). Benefits and risks of oral contraceptives. American journal of obstetrics and gynecology, 180(6), S343-S348.
18. Hall, K. S., White, K. 0. C., Reame, N., & Westhoff, C. (2010). Studying the use of oral contraception: a review of measurement approaches. Journal of Women’s Health, 19(12), 2203-2210.
19. Kuhl, H. (2005). Pharmacology of estrogens and progestogens: influence of different
routes of administration. Climacteric, 8(supl), 3-63.
20. Dhont, M. (2010). History of oral contraception. The European Journal of Contraception & Reproductive Health Care, 15(sup2), Sl2-Sl8.
21. Rowan, J. P., Simon, J. A., Speroff, L., & Ellman, H. (2006). Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 µg) in women with postmenopausal symptoms: Updated analysis of three randomized, controlled trials. Clinical therapeutics, 28(6), 921-932.
22. Regidor, P. A. (2019). Clinical relevance in present day hormonal contraception.
Hormone molecular biology and clinical investigation,37(1), 20180030.
23. Sahu, A, Tripatby, P., Mohanty, J., & Nagy, A. (2019). Doppler analysis of ovarian strnmal blood flow changes after treatment with metformin versus ethinyl estradiol­ cyproterone acetate in women with polycystic ovarian syndrome: A randomized controlJed trial. Journal of gynecology obstetrics and human reproduction, 48(5), 335- 339.
24. Beg, S., Hasnain, M. S., Rahman, M., & Swain, S. (2019). Introduction to quality by design (QbD): fundamentals, principles, and applications. In Pharmaceutical quality by design (pp. 1-17). Academic Press.
25. Patil, A. S., & Pethe, A. M. (2013). Quality by Design (QbD): A new concept for development of quality pharmaceuticals. International journal of pharmaceutical quality assurance, 4(2), 13-19.
26. Mishra, V., Thakur, S., Patil, A., & Shukla, A. (2018). Quality by design (QbD) approaches in current pharmaceutical set-up. Expert opinion on drug delivery, 15(8), 737-758.
27. Wright, K. P., & Johnson, J. V. (2008). Evaluation of extended and continuous use oral contraceptives. Therapeutics and clinical risk management, 4(5), 905-911.
28. Rowe, R. C., Sheskey, P. J., & Quinn, M. E. (Eds.). (2009). Handbook of pharmaceutical excipients (6th ed.). Pharmaceutical Press.
29. Teal, S., & Edelman, A. (2021). Contraception selection, effectiveness, and adverse effects: a review. Jama, 326(24), 2507-2518.
30. Cooper, D. B., Patel, P., & Mahdy, H. (2017). Oral contraceptive pills.
31. Nyol, S., & Gupta, M. M. (2013). Immediate drug release dosage fom1: a review.
Journal of Drug Delivery and Therapeutics, 3(2).
32. Costa-Ramon, A., Daysal, N. M., & Rodriguez-Gonzalez, A. (2023). The Oral Contraceptive Pill and Adolescents’ Mental Health.
33. Miller, P. C., Donaldson, P. J., Basnayake, S., & De Silva, S. V. (1985). The effect of
oral contraceptive formulation and field-workers: A cautionary tale. International Journal of Gynecology & Obstetrics, 23(1), 13-20.
34. Drug Bank Online. (n.d.). Kariva. Retrieved Dec.,02,2023,from https://go.drugbank.com/uneaith/q?searcher=drugs&query=kariva&button=
35. U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (OrangeBook). Retrieved Dec 20, 2023, from https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products­ therapeutic-equivalence-evaluations-orange-book